JP2021503458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021503458A5 JP2021503458A5 JP2020526865A JP2020526865A JP2021503458A5 JP 2021503458 A5 JP2021503458 A5 JP 2021503458A5 JP 2020526865 A JP2020526865 A JP 2020526865A JP 2020526865 A JP2020526865 A JP 2020526865A JP 2021503458 A5 JP2021503458 A5 JP 2021503458A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridine
- carboxamide
- dihydroisoxazolo
- trifluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 45
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 claims description 40
- 125000002947 alkylene group Chemical group 0.000 claims description 34
- -1 -NR 5 2 Chemical group 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000005843 halogen group Chemical group 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 22
- XKDDDACJDNQVRL-UHFFFAOYSA-N 3,4-dihydropyridine-5-carboxamide Chemical compound NC(=O)C1=CN=CCC1 XKDDDACJDNQVRL-UHFFFAOYSA-N 0.000 claims description 20
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 241000700721 Hepatitis B virus Species 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 claims description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 3
- UVHBUEGWJHYBBN-QMMMGPOBSA-N (4S)-3-(2,5-dimethyl-1,3-oxazol-4-yl)-4-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound CC=1OC(=C(N=1)C=1ON=C2C=1[C@@H](N(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F)C)C UVHBUEGWJHYBBN-QMMMGPOBSA-N 0.000 claims description 2
- NZPMJWYBJSSFKB-VIFPVBQESA-N (4S)-3-(5-fluoropyridin-2-yl)-4-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound FC=1C=CC(=NC=1)C=1ON=C2C=1[C@@H](N(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F)C NZPMJWYBJSSFKB-VIFPVBQESA-N 0.000 claims description 2
- IJPFFWANXHQEAV-JTQLQIEISA-N (4S)-3-cyclopentyl-4-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C1(CCCC1)C=1ON=C2C=1[C@@H](N(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F)C IJPFFWANXHQEAV-JTQLQIEISA-N 0.000 claims description 2
- YUSJPDCEFACERX-VIFPVBQESA-N (4S)-4-methyl-3-(1-methylpyrazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@@H]1N(CCC=2C1=C(ON=2)C1=NN(C=C1)C)C(=O)NC1=CC(=C(C(=C1)F)F)F YUSJPDCEFACERX-VIFPVBQESA-N 0.000 claims description 2
- WIOATQYDIZGLSD-VIFPVBQESA-N (4S)-4-methyl-3-(1-methylpyrazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@@H]1N(CCC=2C1=C(ON=2)C=1C=NN(C=1)C)C(=O)NC1=CC(=C(C(=C1)F)F)F WIOATQYDIZGLSD-VIFPVBQESA-N 0.000 claims description 2
- VCPIFUVZLQPSIB-QMMMGPOBSA-N (4S)-4-methyl-3-(2-methyl-1,3-oxazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@@H]1N(CCC=2C1=C(ON=2)C=1N=C(OC=1)C)C(=O)NC1=CC(=C(C(=C1)F)F)F VCPIFUVZLQPSIB-QMMMGPOBSA-N 0.000 claims description 2
- HCHKJQDTHNTDGX-QMMMGPOBSA-N (4S)-4-methyl-3-(2-methyl-1,3-thiazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@@H]1N(CCC=2C1=C(ON=2)C=1N=C(SC=1)C)C(=O)NC1=CC(=C(C(=C1)F)F)F HCHKJQDTHNTDGX-QMMMGPOBSA-N 0.000 claims description 2
- VWQNYYJOLNMUOB-VIFPVBQESA-N (4S)-4-methyl-3-(5-methyl-1,2-oxazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@@H]1N(CCC=2C1=C(ON=2)C1=NOC(=C1)C)C(=O)NC1=CC(=C(C(=C1)F)F)F VWQNYYJOLNMUOB-VIFPVBQESA-N 0.000 claims description 2
- HSGVZSDPMVKESF-SECBINFHSA-N (6R)-3-(2,4-difluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound FC1=C(C=CC(=C1)F)C=1ON=C2C=1CN([C@@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F HSGVZSDPMVKESF-SECBINFHSA-N 0.000 claims description 2
- HSGVZSDPMVKESF-VIFPVBQESA-N (6S)-3-(2,4-difluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound FC1=C(C=CC(=C1)F)C=1ON=C2C=1CN([C@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F HSGVZSDPMVKESF-VIFPVBQESA-N 0.000 claims description 2
- UBWCVCIJBSRHPU-QMMMGPOBSA-N (6S)-3-(2,5-dimethyl-1,3-oxazol-4-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound CC=1OC(=C(N=1)C=1ON=C2C=1CN([C@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F)C UBWCVCIJBSRHPU-QMMMGPOBSA-N 0.000 claims description 2
- XCVNUASPQHJLRG-QMMMGPOBSA-N (6S)-3-(2,5-dioxopyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound O=C1N(C(CC1)=O)C=1ON=C2C=1CN([C@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F XCVNUASPQHJLRG-QMMMGPOBSA-N 0.000 claims description 2
- VWFZDYIVYXOSPI-JTQLQIEISA-N (6S)-3-(3,3-dimethyl-2-oxopyrrolidin-1-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound CC1(C(N(CC1)C=1ON=C2C=1CN([C@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F)=O)C VWFZDYIVYXOSPI-JTQLQIEISA-N 0.000 claims description 2
- MFFVQTFEKWILKO-VIFPVBQESA-N (6S)-3-(5-fluoropyridin-2-yl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound FC=1C=CC(=NC=1)C=1ON=C2C=1CN([C@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F MFFVQTFEKWILKO-VIFPVBQESA-N 0.000 claims description 2
- RFRAXIGRUQDTAG-GXSJLCMTSA-N (6S)-3-[(5R)-5-(methoxymethyl)-2-oxo-1,3-oxazolidin-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound COC[C@H]1CN(C(O1)=O)C=1ON=C2C=1CN([C@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F RFRAXIGRUQDTAG-GXSJLCMTSA-N 0.000 claims description 2
- RFRAXIGRUQDTAG-ONGXEEELSA-N (6S)-3-[(5S)-5-(methoxymethyl)-2-oxo-1,3-oxazolidin-3-yl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound COC[C@@H]1CN(C(O1)=O)C=1ON=C2C=1CN([C@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F RFRAXIGRUQDTAG-ONGXEEELSA-N 0.000 claims description 2
- KJYINAXOIHOZNB-JTQLQIEISA-N (6S)-3-[4-(difluoromethoxy)phenyl]-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound FC(OC1=CC=C(C=C1)C=1ON=C2C=1CN([C@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F)F KJYINAXOIHOZNB-JTQLQIEISA-N 0.000 claims description 2
- ZDVZDGMQWGFYIV-VIFPVBQESA-N (6S)-6-methyl-3-(1-methylpyrazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)C1=NN(C=C1)C ZDVZDGMQWGFYIV-VIFPVBQESA-N 0.000 claims description 2
- GMPGHCABNLUKQH-VIFPVBQESA-N (6S)-6-methyl-3-(1-methylpyrazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)C=1C=NN(C=1)C GMPGHCABNLUKQH-VIFPVBQESA-N 0.000 claims description 2
- MKEGNZBFAXDDQQ-QMMMGPOBSA-N (6S)-6-methyl-3-(2-methyl-1,3-oxazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)C=1N=C(OC=1)C MKEGNZBFAXDDQQ-QMMMGPOBSA-N 0.000 claims description 2
- JSZYIRAJUGCKIQ-QMMMGPOBSA-N (6S)-6-methyl-3-(2-methyl-1,3-thiazol-4-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)C=1N=C(SC=1)C JSZYIRAJUGCKIQ-QMMMGPOBSA-N 0.000 claims description 2
- ICQVPMDDFGFVSX-QMMMGPOBSA-N (6S)-6-methyl-3-(2-oxo-1,3-oxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)N1C(OCC1)=O ICQVPMDDFGFVSX-QMMMGPOBSA-N 0.000 claims description 2
- VRUMABCEOCYRIQ-JTQLQIEISA-N (6S)-6-methyl-3-(2-oxopiperidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)N1C(CCCC1)=O VRUMABCEOCYRIQ-JTQLQIEISA-N 0.000 claims description 2
- VDYQOGFMBFRUAY-ZDUSSCGKSA-N (6S)-6-methyl-3-(2-oxopiperidin-1-yl)-N-phenyl-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC=CC=C1)=C(ON=2)N1C(CCCC1)=O VDYQOGFMBFRUAY-ZDUSSCGKSA-N 0.000 claims description 2
- NEDPNLXVPYPBTE-VIFPVBQESA-N (6S)-6-methyl-3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)N1C(CCC1)=O NEDPNLXVPYPBTE-VIFPVBQESA-N 0.000 claims description 2
- ZIIBJWPMFGZYHC-AXDSSHIGSA-N (6S)-6-methyl-3-(3-methyl-2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)N1C(C(CC1)C)=O ZIIBJWPMFGZYHC-AXDSSHIGSA-N 0.000 claims description 2
- GUYFVZOBYJMYLB-JTQLQIEISA-N (6S)-6-methyl-3-[4-(trifluoromethoxy)phenyl]-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)C1=CC=C(C=C1)OC(F)(F)F GUYFVZOBYJMYLB-JTQLQIEISA-N 0.000 claims description 2
- PIISANBTQLIGPW-JTQLQIEISA-N (6S)-6-methyl-3-morpholin-4-yl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)N1CCOCC1 PIISANBTQLIGPW-JTQLQIEISA-N 0.000 claims description 2
- PPQJTCAMXPUBSU-NSHDSACASA-N (6S)-6-methyl-3-phenyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)C1=CC=CC=C1 PPQJTCAMXPUBSU-NSHDSACASA-N 0.000 claims description 2
- HYKKDULXSMSBBK-NSHDSACASA-N (6S)-N-(3-cyano-4-fluorophenyl)-6-methyl-3-(2-oxopyrrolidin-1-yl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C(#N)C=1C=C(C=CC=1F)NC(=O)N1CC=2C(C[C@@H]1C)=NOC=2N1C(CCC1)=O HYKKDULXSMSBBK-NSHDSACASA-N 0.000 claims description 2
- MGZBOXJGQBWBJN-LBPRGKRZSA-N (6S)-N-(4-cyano-3-fluorophenyl)-6-methyl-3-(2-oxopiperidin-1-yl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C(#N)C1=C(C=C(C=C1)NC(=O)N1CC=2C(C[C@@H]1C)=NOC=2N1C(CCCC1)=O)F MGZBOXJGQBWBJN-LBPRGKRZSA-N 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
- TXWTXQMIYAKTNX-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-4-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound FC1=C(C=CC(=C1)F)C=1ON=C2C=1C(N(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F)C TXWTXQMIYAKTNX-UHFFFAOYSA-N 0.000 claims description 2
- HSGVZSDPMVKESF-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound FC1=C(C=CC(=C1)F)C=1ON=C2C=1CN(C(C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F HSGVZSDPMVKESF-UHFFFAOYSA-N 0.000 claims description 2
- PCEXGHZIDJLECJ-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2,1-benzoxazole-5-carboxamide Chemical compound FC1=C(C=CC(=C1)F)C1=C2C(=NO1)CCC(C2)C(=O)NC1=CC(=C(C(=C1)F)F)F PCEXGHZIDJLECJ-UHFFFAOYSA-N 0.000 claims description 2
- WIAIAMDEYRNDGC-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound FC1=C(C=CC(=C1)F)C=1ON=C2C=1CN(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F WIAIAMDEYRNDGC-UHFFFAOYSA-N 0.000 claims description 2
- UVLPLEKFXBKBKK-UHFFFAOYSA-N 3-(2,4-difluorophenyl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,5-c]pyridine-5-carboxamide Chemical compound FC1=C(C=CC(=C1)F)C1=NOC2=C1CN(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F UVLPLEKFXBKBKK-UHFFFAOYSA-N 0.000 claims description 2
- TULMYEKSAZXSTA-UHFFFAOYSA-N 3-(2-oxo-1,3-oxazolidin-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound O=C1OCCN1C=1ON=C2C=1CN(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F TULMYEKSAZXSTA-UHFFFAOYSA-N 0.000 claims description 2
- VHDQWAUACHPBMC-UHFFFAOYSA-N 3-(2-oxopyrrolidin-1-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound O=C1N(CCC1)C=1ON=C2C=1CN(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F VHDQWAUACHPBMC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
- LSEYORLPHQWFIC-UHFFFAOYSA-N 3-cyclohexyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C1(CCCCC1)C=1ON=C2C=1CN(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F LSEYORLPHQWFIC-UHFFFAOYSA-N 0.000 claims description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 2
- HQUFQKYHNODMHF-UHFFFAOYSA-N 3-pyrrolidin-1-yl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound N1(CCCC1)C=1ON=C2C=1CN(CC2)C(=O)NC1=CC(=C(C(=C1)F)F)F HQUFQKYHNODMHF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 108700024845 Hepatitis B virus P Proteins 0.000 claims description 2
- 229940123066 Polymerase inhibitor Drugs 0.000 claims description 2
- 241000700605 Viruses Species 0.000 claims description 2
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 125000002619 bicyclic group Chemical group 0.000 claims description 2
- 210000000234 capsid Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 230000009545 invasion Effects 0.000 claims description 2
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 2
- 230000029302 virus maturation Effects 0.000 claims description 2
- HUDQNSZHUYMTFV-JTQLQIEISA-N (6S)-3-cyclopentyl-6-methyl-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C1(CCCC1)C=1ON=C2C=1CN([C@H](C2)C)C(=O)NC1=CC(=C(C(=C1)F)F)F HUDQNSZHUYMTFV-JTQLQIEISA-N 0.000 claims 1
- 0 CC(C)(CC1(C)C(C)(*)C1)C1C(C(*)*C(N*)=O)C(*)*C1* Chemical compound CC(C)(CC1(C)C(C)(*)C1)C1C(C(*)*C(N*)=O)C(*)*C1* 0.000 description 7
- XFRUWSLGKIHRNY-QMMMGPOBSA-N (6S)-6-methyl-3-(5-methyl-1,2-oxazol-3-yl)-N-(3,4,5-trifluorophenyl)-6,7-dihydro-4H-[1,2]oxazolo[4,3-c]pyridine-5-carboxamide Chemical compound C[C@H]1CC=2C(CN1C(=O)NC1=CC(=C(C(=C1)F)F)F)=C(ON=2)C1=NOC(=C1)C XFRUWSLGKIHRNY-QMMMGPOBSA-N 0.000 description 1
- VBQIBADYFGDQCN-OCVQLUPQSA-N C[C@@H](Cc1n[s]c(C(CCCC(C2)(C2OC)OC2)C2=O)c1CCC1)C1C(Nc(cc1F)cc(C(C)=C)c1F)=C1CC1 Chemical compound C[C@@H](Cc1n[s]c(C(CCCC(C2)(C2OC)OC2)C2=O)c1CCC1)C1C(Nc(cc1F)cc(C(C)=C)c1F)=C1CC1 VBQIBADYFGDQCN-OCVQLUPQSA-N 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762588122P | 2017-11-17 | 2017-11-17 | |
| US62/588,122 | 2017-11-17 | ||
| US201862727936P | 2018-09-06 | 2018-09-06 | |
| US62/727,936 | 2018-09-06 | ||
| PCT/IB2018/059059 WO2019097479A1 (en) | 2017-11-17 | 2018-11-16 | Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021503458A JP2021503458A (ja) | 2021-02-12 |
| JP2021503458A5 true JP2021503458A5 (https=) | 2021-12-23 |
Family
ID=64572418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020526865A Withdrawn JP2021503458A (ja) | 2017-11-17 | 2018-11-16 | 新規のジヒドロイソキサゾール化合物及びｂ型肝炎治療のためのそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210079015A1 (https=) |
| EP (1) | EP3710455A1 (https=) |
| JP (1) | JP2021503458A (https=) |
| CN (1) | CN111315749A (https=) |
| WO (1) | WO2019097479A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016183266A1 (en) | 2015-05-13 | 2016-11-17 | Enanta Pharmaceuticals, Inc. | Ehpatitis b antiviral agents |
| KR102398439B1 (ko) | 2016-03-07 | 2022-05-16 | 이난타 파마슈티칼스, 인코포레이티드 | B형 간염 항바이러스제 |
| SG11202001685TA (en) | 2017-08-28 | 2020-03-30 | Enanta Pharm Inc | Hepatitis b antiviral agents |
| SG11202004594SA (en) * | 2017-11-16 | 2020-06-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds |
| AU2018391977A1 (en) * | 2017-12-21 | 2020-05-21 | Janssen Sciences Ireland Unlimited Company | Isoxazole compounds for the treatment of diseases associated with HBV infections |
| US11058678B2 (en) | 2018-01-22 | 2021-07-13 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| WO2019191166A1 (en) | 2018-03-29 | 2019-10-03 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| JP2022500466A (ja) | 2018-09-21 | 2022-01-04 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス剤としての官能化複素環 |
| IL283190B2 (en) | 2018-11-21 | 2025-08-01 | Enanta Pharm Inc | Functionalized heterocycles as antiviral agents |
| WO2020247444A1 (en) | 2019-06-03 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| WO2020247575A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc. | Hepatitis b antiviral agents |
| WO2020247561A1 (en) | 2019-06-04 | 2020-12-10 | Enanta Pharmaceuticals, Inc, | Hepatitis b antiviral agents |
| US11738019B2 (en) | 2019-07-11 | 2023-08-29 | Enanta Pharmaceuticals, Inc. | Substituted heterocycles as antiviral agents |
| US11236108B2 (en) | 2019-09-17 | 2022-02-01 | Enanta Pharmaceuticals, Inc. | Functionalized heterocycles as antiviral agents |
| WO2021188414A1 (en) | 2020-03-16 | 2021-09-23 | Enanta Pharmaceuticals, Inc. | Functionalized heterocyclic compounds as antiviral agents |
| MX2022015311A (es) * | 2020-06-05 | 2023-02-22 | Pathios Therapeutics Ltd | N-(fenilaminocarbonil) tetrahidro-isoquinolinas y compuestos relacionados como moduladores de gpr65. |
| GB202103704D0 (en) * | 2021-03-17 | 2021-04-28 | Pathios Therapeutics Ltd | Compounds |
| CN114539148A (zh) * | 2022-01-25 | 2022-05-27 | 北京英飞智药科技有限公司 | 一种环状n-羟基酰亚胺类化合物及其用途 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0090505B1 (en) | 1982-03-03 | 1990-08-08 | Genentech, Inc. | Human antithrombin iii, dna sequences therefor, expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby, a process for expressing human antithrombin iii, and pharmaceutical compositions comprising it |
| US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
| ES2308787T3 (es) | 1996-08-16 | 2008-12-01 | Schering Corporation | Antigenos de superficie de celular de mamiferos; reactivos relacionados. |
| JP2001520039A (ja) | 1997-10-21 | 2001-10-30 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ヒト腫瘍壊死因子レセプター様タンパク質、ｔｒ１１，ｔｒ１１ｓｖ１およびｔｒ１１ｓｖ２ |
| AU2591599A (en) | 1998-02-09 | 1999-08-23 | Genentech Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
| WO2001003720A2 (en) | 1999-07-12 | 2001-01-18 | Genentech, Inc. | Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| US7618632B2 (en) | 2003-05-23 | 2009-11-17 | Wyeth | Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies |
| WO2005007190A1 (en) | 2003-07-11 | 2005-01-27 | Schering Corporation | Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer |
| WO2005055808A2 (en) | 2003-12-02 | 2005-06-23 | Genzyme Corporation | Compositions and methods to diagnose and treat lung cancer |
| GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
| US20060002932A1 (en) | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007133822A1 (en) | 2006-01-19 | 2007-11-22 | Genzyme Corporation | Gitr antibodies for the treatment of cancer |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| NZ590667A (en) | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| JP2012500855A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法 |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| CN102149820B (zh) | 2008-09-12 | 2014-07-23 | 国立大学法人三重大学 | 能够表达外源gitr配体的细胞 |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| JP5977347B2 (ja) * | 2011-07-01 | 2016-08-24 | バルーク エス．ブルームバーグ インスティテュート | Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体 |
| WO2013039954A1 (en) | 2011-09-14 | 2013-03-21 | Sanofi | Anti-gitr antibodies |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| BR112014015197A8 (pt) | 2011-12-21 | 2017-06-13 | Novira Therapeutics Inc | agentes antivirais de hepatite b |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| EP3670496A3 (en) | 2013-10-17 | 2020-09-30 | Shionogi&Co., Ltd. | Acc2 inhibitors |
| EA201691261A1 (ru) | 2014-01-30 | 2016-11-30 | Ф. Хоффманн-Ля Рош Аг | Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b |
| AU2015226206B2 (en) | 2014-03-07 | 2017-03-16 | F. Hoffmann-La Roche Ag | Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection |
| KR20160148715A (ko) | 2014-05-13 | 2016-12-26 | 에프. 호프만-라 로슈 아게 | B형 간염 바이러스 감염의 치료 또는 예방을 위한 신규한 다이하이드로퀴놀리진온 |
| WO2016109684A2 (en) * | 2014-12-30 | 2016-07-07 | Novira Therapeutics, Inc. | Derivatives and methods of treating hepatitis b infections |
| MA41338B1 (fr) * | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| WO2018011163A1 (en) | 2016-07-14 | 2018-01-18 | F. Hoffmann-La Roche Ag | 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases |
| SG11202004594SA (en) * | 2017-11-16 | 2020-06-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds |
-
2018
- 2018-11-16 US US16/764,525 patent/US20210079015A1/en not_active Abandoned
- 2018-11-16 CN CN201880072633.XA patent/CN111315749A/zh active Pending
- 2018-11-16 WO PCT/IB2018/059059 patent/WO2019097479A1/en not_active Ceased
- 2018-11-16 JP JP2020526865A patent/JP2021503458A/ja not_active Withdrawn
- 2018-11-16 EP EP18812295.6A patent/EP3710455A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021503458A5 (https=) | ||
| RU2485114C2 (ru) | Карбоксамидные соединения и их применение в качестве ингибиторов кальпаинов | |
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| JP2018530571A5 (https=) | ||
| JP2007510689A5 (https=) | ||
| JP2013544893A5 (https=) | ||
| JPWO2022230912A5 (https=) | ||
| HRP20150082T1 (hr) | Derivati pirazolo piridina kao inhibitori nadph oksidaze | |
| JP2008516986A5 (https=) | ||
| RU2011116232A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| RU2016141645A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2017525757A5 (https=) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2017508766A5 (https=) | ||
| ME02906B (me) | Derivati pirazolopirolidina i njihova upotreba u liječenju bolesti | |
| RU2007132262A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| JP2007519694A5 (https=) | ||
| RU2002134487A (ru) | Бензофены как ингибиторы il-1бета и tnf-альфа | |
| JP2022548602A5 (https=) | ||
| JP2016537384A5 (https=) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| IL291181B1 (en) | Pyridazine–3(H2)–one–fused–azole derivatives | |
| JP2017512786A5 (https=) | ||
| JP2017501983A5 (https=) | ||
| RU2006143571A (ru) | Производные пирразолпиримидина |